Study Findings Complicate the Paradigm for Hormone-Sensitive Prostate Cancer May 21, 2018 Clinical trial results that challenge the standard of care sometimes make it more difficult for physicians to decide how to treat their patients. Such is the case with the CHAARTED, LATITUDE, and STAMPEDE trials1-3, which demonstrate the heterogeneous nature of prostate cancer and its subtypes, highlighting the importance of a more cautious approach in choosing therapies for patients with metastatic hormone-sensitive prostate cancer (mHSPC).Read more. Source: Ariela Katz - OncLive Prostate Cancer News
Clinical trial results that challenge the standard of care sometimes make it more difficult for physicians to decide how to treat their patients. Such is the case with the CHAARTED, LATITUDE, and STAMPEDE trials1-3, which demonstrate the heterogeneous nature of prostate cancer and its subtypes, highlighting the importance of a more cautious approach in choosing therapies for patients with metastatic hormone-sensitive prostate cancer (mHSPC).Read more. Source: Ariela Katz - OncLive
